Drug Target Review

AUGUST 25, 2023

However, in tissues where the 3 Hs are not present, the small molecule has anti-toxicity activity through 1) direct inhibition of the NLRP3 inflammasome, an inflammation starter and perpetuator, and 2) upregulation of the master antioxidant transcription factor, Nrf2. Also, unlike several other viruses, AdAPT-001 is deliverable systemically.

Small Molecule 98

Small Molecule Virus International Clinical Trials 98

The Pharma Data

MARCH 8, 2021

The companies today reported findings on one secondary objective from the Phase 2a study, showing a reduction in time (days) to negativity of infectious virus isolation in nasopharyngeal swabs from participants with symptomatic SARS-CoV-2 infection, as determined by isolation in Vero cell line culture. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

PLOS: DNA Science

JUNE 26, 2025

The planet presents many ecosystems, natural or not, to probe. Team leader David Duffy, professor of wildlife disease genomics at the University of Florida‘s Whitney Laboratory for Marine Bioscience, was surprised at the ease of sampling and analyzing the eDNA.

DNA 56

DNA Bioethics Science Laboratories 56

The Pharma Data

APRIL 26, 2022

NYSE: PFE) today reported positive Phase 2 pediatric data for their Lyme disease vaccine candidate, VLA15. Valneva and Pfizer plan to submit these data for publication and presentation at a future scientific congress. About VLA15 VLA15 is the only Lyme disease vaccine candidate currently in clinical development.

Vaccine 52

Vaccine Disease Protein Expression Trials 52

Drug Target Review

NOVEMBER 24, 2023

The use of nanoparticles, which are around the size of a virus particle, is a very promising delivery method for overcoming chemotherapy issues. Macrophages typically consume and clear pathogens and then present the pathogen parts to T cells. The T cells then give an antigen-specific response to recognise that specific pathogen.

Immune Response 111

Immune Response Pharmacy Treatment Virus 111

DrugBank

MARCH 12, 2025

However, mRNA technology is not limited to infectious diseases. This unique mechanism has enabled scientists to rethink how they tackle diseases, paving the way for advancements in oncology, genetic disorders, and regenerative medicine. 

Vaccine 97

Vaccine Treatment Clinical Trials Therapies 97

Drug Target Review

SEPTEMBER 11, 2023

While the concept of removing mucins from cancer cells seems promising, mucins are present in various forms on all mammalian cells. Their findings, published in Nature Biotechnology, have broad applications as mucins are associated with many diseases, including cystic fibrosis, respiratory diseases, and viruses.

Immune Response 116

Immune Response Research Virus Engineering 116

The Pharma Data

DECEMBER 5, 2020

The data is being presented today in oral presentations at the 62nd American Society of Hematology (ASH) Annual Meeting. The new data presented today strengthen our conviction that SY-1425 has the potential to become the foundation of care for all RARA-positive patients,” said David A. Chief Medical Officer of Syros.

Clinical Trials 52

Clinical Trials Trials Small Molecule Treatment 52

Drug Target Review

SEPTEMBER 28, 2023

They needed reference materials for the disease in order to develop and validate diagnostic tests. For security reasons, at the time COVID-19 had to be grown in BSL-3 labs, which can be dangerous because they were handling the live virus. These are synthetic, not the live virus, so do not pose a risk of infection.

DNA 116

DNA Organic Chemistry Science Virus 116

The Pharma Data

NOVEMBER 11, 2020

“As an orally bioavailable small molecule with broad antiviral activity, SLV213 could be a valuable treatment to meet today’s urgent need to fight COVID-19 as well other life-threatening infectious diseases, such as Chagas disease, Ebola virus disease, and Nipah virus infection.”.

Treatment 52

Treatment Small Molecule Virus Pharmacokinetics 52

Drug Target Review

OCTOBER 25, 2023

These white blood cells destroy diseased cells around the body, but in early pregnancy these natural killer cells in the decidua play a key role in the vast tissue and blood vessel remodelling required for the placenta to properly develop and for the foetus to begin receiving nutrients and oxygen from the parent.

Treatment 105

Treatment Virus Research Science 105

Drug Target Review

SEPTEMBER 25, 2024

5 Here, the original oncogene is still present but the transdifferentiated cancer cells are less dependent on it. Investigating non-oncogene resistance as a parallel defense mechanism used by cancer cells to evade therapies could therefore present a significant opportunity to address drug resistance more comprehensively.

Small Molecule 105

Small Molecule Therapies Regulations Treatment 105

The Pharma Data

JUNE 25, 2021

Nasdaq: NVAX), today announced that NVX-CoV2373, its recombinant nanoparticle protein-based COVID-19 vaccine, demonstrated 100% protection against moderate and severe disease, 90.4% 100) against moderate or severe disease. Variant Virus Strains. Novavax, Inc. The study enrolled 29,960 participants across 119 sites in the U.S.

Vaccine 40

Vaccine Trials Disease Immune Response 40

The Pharma Data

JULY 12, 2021

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics announced today the presentation of previously announced Phase 2 interim results from two Phase 2/3 clinical trials (MOVe-OUT and MOVe-IN) of molnupiravir (MK-4482/EIDD-2801), an investigational oral antiviral therapeutic. About Molnupiravir.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

The Pharma Data

AUGUST 1, 2021

It is not known whether the impairment, such as forgetfulness and language difficulty, will be progressive, said Gabriel de Erausquin, MD, PhD, a neurologist with the health science center’s Glenn Biggs Institute for Alzheimer’s and Neurodegenerative Diseases. Presented at the Alzheimer’s Association International Conference, July 29, 2021.

Virus 52

Virus International Science Disease 52

Creative Biolabs

JUNE 2, 2020

At present, this antibody, called S309, has entered the track of rapid development and testing in Vir Biotechnology, and clinical trials may be carried out in the next step. It can neutralize SARS-CoV-2 virus by binding to the S protein fragment near the attachment site of the host cell.

Virus 52

Virus Clinical Trials Research Treatment 52

The Pharma Data

NOVEMBER 23, 2020

. Positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil showed the vaccine was highly effective in preventing COVID-19, the primary endpoint, and no hospitalisations or severe cases of the disease were reported in participants receiving the vaccine. AstraZeneca.

Vaccine 52

Vaccine Virus Trials Clinical Trials 52

The Pharma Data

AUGUST 16, 2021

During challenge with the original SARS-CoV-2 virus, animals vaccinated with CV2CoV were found to be better protected based on highly effective clearance of the virus in the lungs and nasal passages. Clearance of the virus in the lungs and nasal passages of the animals was tested following challenge infection with the original virus.

Immune Response 52

Immune Response Vaccine Virus RNA 52

New Drug Approvals

SEPTEMBER 6, 2024

US10071079, Example 15 Ref WO2018005586 [link] The invention further pertains to pharmaceutical compositions containing at least one compound according to the invention that are useful for the treatment of conditions related to TLR modulation, such as inflammatory and autoimmune diseases, and methods of inhibiting the activity of TLRs in a mammal.

RNA 62

RNA Clinical Trials DNA Disease 62

The Pharma Data

JUNE 25, 2021

In the unprecedented context of at least 13 variants circulating within the study population subset assessed at this interim analysis, CVnCoV demonstrated an interim vaccine efficacy of 47% against COVID-19 disease of any severity and did not meet prespecified statistical success criteria. 37, first identified in Peru (21%) and B.1.621,

Vaccine 52

Vaccine Trials Immune Response Virus 52

Drug Target Review

SEPTEMBER 8, 2023

Remarkably, these findings propose that the presence of a cytoplasmic version of RARα is indispensable for T cells to initiate their defence against diseases. The researchers speculate that this mechanism could serve as a valuable target for combating autoimmune diseases and other inflammatory conditions.

Regulations 98

Regulations Research DNA Immune Response 98

The Pharma Data

DECEMBER 16, 2020

Nasdaq: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced an Advance Purchase Agreement with the government of New Zealand for the purchase of 10.7 GAITHERSBURG, Md., 16, 2020 (GLOBE NEWSWIRE) — Novavax , Inc. About NVX-CoV2373. About Novavax. Novavax, Inc.?(Nasdaq:

Vaccine 52

Vaccine Government Immune Response Clinical Trials 52

The Pharma Data

JULY 6, 2021

If a virus is disease-causing, the right mutation can allow the virus to escape the immune response by changing the viral pieces the immune system uses to recognize the virus as a threat, pieces scientists call epitopes. ” You can think of a virus’s structure like the design of a house, explains Nathan. .

Vaccine 52

Vaccine Virus Research Immune Response 52

The Pharma Data

SEPTEMBER 16, 2020

Seven officials working for the administration both currently and in the past have alleged that the HHS Secretary moved in late August to revoke the FDA’s ability to evaluate the quality of “lab-developed” tests for a range of diseases including COVID-19, as reported by Politico. Matt Fellows. Source link.

FDA 52

FDA Virus Marketing Disease 52

NIH Director's Blog: Drug Development

APRIL 2, 2020

With so much information swirling around these days about the coronavirus disease 2019 (COVID-19) pandemic, it would be easy to miss one of the most interesting and significant basic science reports of the past few weeks. ACE2 is the receptor that the virus uses to gain entry.

Drug Development 52

Drug Development Drugs Science Medical Schools 52

The Pharma Data

OCTOBER 27, 2020

28, 2020 /PRNewswire/ — Pathnostics , a diagnostic solutions company, today announced that it has launched a multiplex polymerise chain reaction (PCR) test that simultaneously detects multiple respiratory infections, including COVID-19, influenzas A/B and respiratory syncytial virus (RSV). IRVINE, Calif. ,

Virus 52

Virus Disease Production 52

The Pharma Data

MARCH 20, 2021

Patients with COVID-19 present with upper respiratory infections that can result in a number of complications particularly in patients of advanced age or with co-morbidities. Accurate and timely laboratory diagnosis of COVID-19 is one of the most pivotal requirements for optimal disease management and contact tracing. INTRODUCTION.

Virus 52

Virus Assay Development Laboratories RNA 52

The Pharma Data

DECEMBER 10, 2020

In the study, immunization with the hAd5-COVID-19 vaccine inhibited SARS-CoV-2 virus replication in 100% (10 of 10) of Rhesus macaques, with a drop in viral replication starting on the first day of vaccine administration, and undetectable viral levels as early as three to five days post-challenge in most of the animals.

Vaccine 52

Vaccine Immune Response Virus Clinical Trials 52

The Pharma Data

OCTOBER 30, 2020

Since the outbreak of the novel coronavirus spread across the globe, doctors and public health officials have warned of particular symptoms associated with the virus, including a dry cough, fever and shortness of breath, among others, such as headache, chills or a sore throat. Centers for Disease Control and Prevention common to COVID-19.

Doctors 52

Doctors Virus Disease Treatment 52

The Pharma Data

SEPTEMBER 1, 2020

This can help healthcare professionals identify a SARS-CoV-2 infection in people suspected to carry the virus with results typically ready in 15 minutes. The SARS-CoV-2 Rapid Antigen Test is for use in point of care settings for both symptomatic and asymptomatic people.

Virus 52

Virus Laboratories Clinical Trials Treatment 52

The Pharma Data

NOVEMBER 23, 2020

Studies funded by a number of grants in the beginning of May are already providing insight into why the virus seems to affect the cardiac system, Lloyd-Jones said. 13 to 15 in Boston, will be presented in a hybrid format offering either in-person or virtual attendance. The meeting, to be held Nov. More Information. © 2020 HealthDay.

Research 52

Research Virus Therapies Trials 52

DrugBank

JANUARY 29, 2025

Each of these mechanisms represents a distinct strategy to address the underlying genetic perturbations contributing to disease pathogenesis. In sickle cell disease, for instance, a missense mutation in the HBB gene , encoding the beta-globin subunit of hemoglobin, leads to the production of abnormal hemoglobin S.

Therapies 52

Therapies DNA RNA Disease 52

The Pharma Data

DECEMBER 28, 2020

Moleculin recently announced that the FDA had allowed its request for Investigational New Drug (IND) status for Annamycin, allowing Moleculin to begin a Phase 1B /2 clinical trial in the US for patients with soft tissue sarcoma (STS) that has metastasized to the lungs after first-line therapy for their disease. .

FDA 52

FDA Clinical Trials Drugs Pharmaceutical Companies 52

The Pharma Data

JANUARY 31, 2021

On the heels of our recent COVID-19 program initiation in partnership with the NIH, this program adds to our growing infectious disease pipeline supported by collaborations with leading biopharma and renowned institutions.”. This press release features multimedia.

Vaccine 52

Vaccine Science Clinical Trials Licensing 52

The Pharma Data

APRIL 26, 2022

Machine-learning models can propose new molecules that have specific properties which could fight certain diseases, doing in minutes what might take humans months to achieve manually. If a chemist can’t actually make the molecule, its disease-fighting properties can’t be tested. Building blocks.

Drugs 52

Drugs Engineering Disease Research 52

Alta Sciences

JULY 25, 2024

Watch the poster presentation. In this eBook, discover the different requirements, procedures, and timelines based on where you choose to conduct your studies—whether in Canada, the U.S., the UK, or the EU. Read the eBook.

Science 52

Science Clinical Trials Clinical Pharmacology FDA 52

The Pharma Data

OCTOBER 14, 2020

The research is part of an ongoing collaboration between Columbia University and Tonix that focuses on T cell and antibody responses to SARS-CoV-2 (CoV-2), the virus that causes COVID-19. The immunology portfolio includes vaccines to prevent infectious diseases and biologics to address immunosuppression, cancer and autoimmune diseases.

Vaccine 40

Vaccine Pharmaceuticals Small Molecule Virus 40